PAVM News and Press, PAVmed Inc. From 12/09/25

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection PR Newswire Report includes nearly 12,000 patients who underwent Lucid's EsoGuard ® Esophageal DNA Test on samples collected using its EsoCheck ® ...

2025-12-05 11:08:49 ET PAVmed Inc. (PAVM) Shareholder/Analyst Call December 5, 2025 10:00 AM EST Company Participants Lishan Aklog - Chairman & CEO Michael Gordon - Executive VP, General Counsel & Secretary ... Read the full article on Seeking Alpha ...

Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree PR Newswire Recognized as the leading company in its size category in program honoring the top workplaces across the diagnostics and precision-medicine sectors NEW YORK , Nov. 20, 2025 /PRNe...

2025-11-13 11:31:34 ET PAVmed Inc. (PAVM) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants Matt Riley Lishan Aklog - Chairman & CEO Dennis McGrath - President & CFO Conference Call Participants Anthony Vendetti - Ma...

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire NEW YORK , Nov. 13, 2025 ...

PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results PR Newswire Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor PAVmed signed letter of intent (LOI) to license ground...

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...

2025-11-12 08:07:14 ET More on PAVmed PAVmed Q3 2025 Earnings Preview Seeking Alpha’s Quant Rating on PAVmed Historical earnings data for PAVmed Financial information for PAVmed Read the full article on Seeking Alpha For further details...

Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results PR Newswire Processed 2,841 EsoGuard ® tests and recognized 3Q25 revenue of $1.2 million , ending quarter with over $47 million in proforma cash and extending runway through 2026 an...

2025-11-11 11:52:18 ET More on PAVmed PAVmed Q2 2025 Earnings Preview Seeking Alpha’s Quant Rating on PAVmed Historical earnings data for PAVmed Financial information for PAVmed Read the full article on Seeking Alpha For further details...